HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Statins in neurological disorders: an overview and update.

Abstract
Statins have, at present, the potential to provide a new therapeutic target for various neurological diseases. It is well established that statins reduce cholesterol levels and prevent coronary heart disease. Moreover, evidence suggest that statins have additional properties such as endothelial protection via action on the nitric oxide synthase system as well as antioxidant, anti-inflammatory and anti-platelet effects. These properties might have potential therapeutic implication not only in stroke but also in neurological disorders such as Alzheimer disease, Parkinson's disease, multiple sclerosis and primary brain tumors. In addition to their potent anti-atherosclerotic and cardio-protective effects, compelling clinical and preclinical studies delineate the neuro-protective efficacy of statins in all these neurological disorders. It is apparent from these studies that most patients with central nervous system disorders probably benefit to some extent from lipid-lowering therapy. But data are not univocal, and we must also consider the adverse effects due to the administration of lipid-lowering therapy. Thus, in these scenarios the effectiveness of statins in treating stroke, Alzheimer's disease, Parkinson disease, multiple sclerosis, and primary brain tumors have to be conclusively proven in vivo and/or in adequate clinical trials.
AuthorsAnna Maria Malfitano, Giuseppe Marasco, Maria Chiara Proto, Chiara Laezza, Patrizia Gazzerro, Maurizio Bifulco
JournalPharmacological research (Pharmacol Res) Vol. 88 Pg. 74-83 (Oct 2014) ISSN: 1096-1186 [Electronic] Netherlands
PMID24954580 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
CopyrightCopyright © 2014 Elsevier Ltd. All rights reserved.
Chemical References
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Neuroprotective Agents
  • Reactive Oxygen Species
  • Nitric Oxide Synthase Type III
  • NADPH Oxidases
  • Matrix Metalloproteinases
Topics
  • Animals
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors (pharmacology, therapeutic use)
  • Matrix Metalloproteinases (metabolism)
  • NADPH Oxidases (metabolism)
  • Nervous System Diseases (drug therapy)
  • Neuroprotective Agents (pharmacology, therapeutic use)
  • Nitric Oxide Synthase Type III (metabolism)
  • Reactive Oxygen Species (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: